Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 950693, 13 pages
http://dx.doi.org/10.1155/2012/950693
Review Article

Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease

Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Saitama, Sakado 350-0295, Japan

Received 23 July 2012; Accepted 13 November 2012

Academic Editor: Stephen D. H. Malnick

Copyright © 2012 Kei Nakajima. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [15 citations]

The following is the list of published articles that have cited the current article.

  • Vera J. Goh, “The Lipid Droplet as a Potential Therapeutic Target in NAFLD,” Seminars in Liver Disease, vol. 33, no. 4, pp. 312–320, 2013. View at Publisher · View at Google Scholar
  • Nicolas Wiernsperger, “Hepatic function and the cardiometabolic syndrome,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 379–388, 2013. View at Publisher · View at Google Scholar
  • Wouter De Haes, Lotte Frooninckx, Roel Van Assche, Arne Smolders, Geert Depuydt, Johan Billen, Bart P. Braeckman, Liliane Schoofs, and Liesbet Temmerman, “Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2,” Proceedings of The National Academy of Sciences of The United States of America, vol. 111, no. 24, pp. E2501–E2509, 2014. View at Publisher · View at Google Scholar
  • Samir Rouabhia, Natasa Milic, and Ludovico Abenavoli, “Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism,” Expert Review of Gastroenterology & Hepatology, pp. 1–7, 2014. View at Publisher · View at Google Scholar
  • Yusuf Yilmaz, “Obesity-Associated Nonalcoholic Fatty Liver Disease,” Clinics in Liver Disease, vol. 18, no. 1, pp. 19–+, 2014. View at Publisher · View at Google Scholar
  • Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci, and Guglielmo M Trovato, “4Ps medicine of the fatty liver: The research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics,” EPMA Journal, vol. 5, no. 1, 2014. View at Publisher · View at Google Scholar
  • Nirav Gandhi, Richard Lenton, Mithun Bhartia, Ahmed Abbas, Jessie Raju, and Sudarshan Ramachandran, “Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome,” Springerplus, vol. 3, 2014. View at Publisher · View at Google Scholar
  • Richele L. Corrado, Dawn M. Torres, and Stephen A. Harrison, “Review of Treatment Options for Nonalcoholic Fatty Liver Disease,” Medical Clinics of North America, vol. 98, no. 1, pp. 55–72, 2014. View at Publisher · View at Google Scholar
  • Suja Rani Sasidharan, Joshua Allan Joseph, Senthilkumar Anandakumar, Vijayabalaji Venkatesan, Chandrasekharan Nair Ariyattu Madhavan, and Amit Agarwal, “Ameliorative Potential of Tamarindus indica on High Fat Diet Induced Nonalcoholic Fatty Liver Disease in Rats,” The Scientific World Journal, vol. 2014, pp. 1–10, 2014. View at Publisher · View at Google Scholar
  • Ravirajsinh Jadeja, Ranjitsinh V. Devkar, and Srinivas Nammi, “Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis: Current Scenario and Future Prospects,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, pp. 1–18, 2014. View at Publisher · View at Google Scholar
  • Weidong Xie, Shaobo Zhang, Fan Lei, Xiaoxi Ouyang, and Lijun Du, “ Ananas comosus L. Leaf Phenols and p-Coumaric Acid Regulate Liver Fat Metabolism by Upregulating CPT-1 Expression ,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, pp. 1–12, 2014. View at Publisher · View at Google Scholar
  • Zobair M. Younossi, Li Zheng, Maria Stepanova, Linda Henry, Chapy Venkatesan, and Alita Mishra, “Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease,” Journal of Clinical Gastroenterology, vol. 49, no. 3, pp. 222–227, 2015. View at Publisher · View at Google Scholar
  • Meng-ge Zhao, Xue-ping Sheng, Ya-ping Huang, Yi-ting Wang, Cui-hua Jiang, Jian Zhang, and Zhi-qi Yin, “Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates non-alcoholic fatty liver disease via improving oxidative stress and mitochondrial dysfunction,” Biomedicine & Pharmacotherapy, vol. 104, pp. 229–239, 2018. View at Publisher · View at Google Scholar
  • Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, and Sergio H. S. Santos, “The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review,” Hypertension Research, 2018. View at Publisher · View at Google Scholar
  • Eman F. Khaleel, and Ghada A. Abdel-Aleem, “Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation,” Archives of Physiology and Biochemistry, pp. 1–15, 2018. View at Publisher · View at Google Scholar